POMPANO BEACH, Fla., March 31, 2026 — BioStem Technologies Inc.(OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced…
POMPANO BEACH, Fla., March 30, 2026 (GLOBE NEWSWIRE) — BioStem Technologies, Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today…
POMPANO BEACH, FL, March 24, 2026 (GLOBE NEWSWIRE) — BioStem Technologies, Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products,…
POMPANO BEACH, Fla., March 23, 2026 (GLOBE NEWSWIRE) — BioStem Technologies (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound…
POMPANO BEACH, Fla., March 11, 2026 (GLOBE NEWSWIRE) — BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products for regenerative…
Chronic wounds are not just slow-healing injuries. They are complex medical conditions that often reflect deeper systemic challenges—and in veteran populations, those challenges are frequently compounded. For clinicians caring for…
POMPANO BEACH, Fla., February 3, 2026 (GLOBE NEWSWIRE) — BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of perinatal tissue derived products…
POMPANO BEACH, FL, January 21, 2026 (GLOBE NEWSWIRE) — BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental derived products for advanced wound care, today announced the closing of a definitive asset purchase agreement with BioTissue Holdings Inc, a pioneer and leader…
Decision ensures continued patient access to VENDAJE® and VENDAJE AC® POMPANO BEACH, Fla., Jan. 07, 2026 (GLOBE NEWSWIRE) — BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing,…
Status Quo designation preserves DFU/VLU reimbursement eligibility for 2026, ensuring continued patient access to BioStem technology Coverage for the majority of BioStem’s non-acute revenue, treatment for pressure ulcers, also remains…
